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Interferon gamma release assays (IGRAs) are in vitro immunologic diagnostic tests used to identify Mycobacterium tuberculosis
infection. They cannot diﬀerentiate between latent and active infections. The cutoﬀ suggested by the manufacturer is 0.35IU/mL
for latent tuberculosis. As IGRA tests were recently approved for the diﬀerential diagnosis of active tuberculosis, we assessed
the diagnostic accuracy of the latest generation IGRA for detection of active tuberculosis in a low-incidence area in Germany.
Our consecutive case series includes 61 HIV negative, Mycobacterium tuberculosis culture positive patients, as well as 234 control
patients.Theretrospective analysiswasperformed overaperiodoftwoyears.In11/61patientswithactivetuberculosis (18.0%)the
test result was <0.35IU/mL, resulting in a sensitivity of 0.82. We recommend establishing a new cut-oﬀ v a l u ef o rt h ed i ﬀerential
diagnosis of active tuberculosis assessed by prospective clinical studies and in various regions with high and low prevalence of
tuberculosis.
1.Introduction
Tuberculosis (TB) remains a major public health problem
aﬀecting one-third of the world’s population [1, 2]. Diagno-
sis of TB is usually based on a combination of anamnestic
symptoms, clinical presentation, radiological and patho-
logical changes, bacteriological ﬁndings of acid/alcohol-fast
bacilli, and molecular tests [3]. Deﬁnitive TB diagnosis
is based on the detection of Mycobacterium tuberculosis
(MTB) in the culture, which usually takes four to six weeks.
For decades, tuberculin skin test (TST) has been used as
diagnostic tool to support the physician’s decision process.
With the introduction of interferon gamma release assays
(IGRAs),amorespeciﬁcmethodbecameavailable.Although
primarily developed for the diagnosis of latent TB, clinicians
have also been searching for improved diagnostic tools and
explored IGRAs for the immunodiagnosis of active TB.
In 2010, the Centers for Disease Control and Prevention
(CDC) updated their guidelines for testing for TB infection,
concluding that IGRAs “may be used instead of a tuberculin
skin test in all situations in which the CDC recommends the
tuberculin skin test as an aid in diagnosing M. tuberculosis
infection” [4, 5].
Nevertheless, with the cutoﬀ for the diagnosis of latent
TB as given by the producers, pooled sensitivity for the
diagnosis of culture positive TB did not exceed 80% in the
most recentmeta-analyses [6,7].The present caseseries con-
stitutes one of the largest reports of latest generation IGRA
used in culturally proven HIV-negative TB cases in a low-
prevalence country. Our study is meant to help evaluate the
cutoﬀ for the IGRA in the diﬀerential diagnosis of TB.
2.StudyPopulationand Methods
This is a retrospective study performed on inpatients of a
regional hospital specialized in lung diseases (Lungenklinik
Heckeshorn, Berlin). At least one IGRA is routinely per-
formed on a blood sample of each TB-suspect patient, and
every suspicious sample (smear, lymph node biopsy, pleu-
ral eﬀusion, or biopsy) is routinely cultured for TB. All2 Tuberculosis Research and Treatment
Table 1:(a)MedianandrangeforpatientageandIGRA testresult forallculturepositivecasesofactivetuberculosis, byorganmanifestation.
(b) Median and range for age and IGRA test result for all controls, by diagnosis. “Others” includes other lung diseases such as asbestosis,
aspergillosis, asthma, bronchiectasis, pleural eﬀusion, haemoptysis, ﬁbrosis, and sarcoidosis. (c) Study results for TB cases and controls. (n:
sample size, CI: conﬁdence interval).
(a)
MTB infection Male Female Total Median age, years (range) Median QFT, IU/mL (range)
Lung 28 25 53 45 (4–83) 2.40 (0,00–103,4)
Pleura 2 3 5 26 (17–76) 2,45 (0,96–300)
Lymph node 2 1 3 65 (25–69) 21,32 (3,78–86,8)
Total 32 29 61 46 (5–84) 3.46 (0,00–300)
(b)
Diagnosis Male Female Total Median age, years (range) Median QFT, IU/mL (range)
Malignancy 22 23 45 69 (39–90) 0,01 (0,00–23,9)
Bronchitis 27 13 40 64 (1–90) 0,00 (0,00–1,84)
Pneumonia 30 17 47 67 (1–99) 0,00 (0,00–75)
Others 53 49 102 62,5 (5–99) 0,02 (0,00–103,4)
Total 132 102 234 66 (1–99) 0,00 (0,00–103,4)
(c)
n QFT Age
Mean 95% CI P Mean 95% CI P
TB 61 14.13 3.44–24.82 <0.05 47.8 41.88–53.79 <0.05
Control 234 1.33 0.24–2.43 63 60.56–65.39
samples of patients included in this study were taken prior
to initiation of antibiotic therapy. Over a two-year period
(1/2008–1/2010), IGRA results of all MTB culture positive
cases of active TB were analyzed. Patients with other lung
diseases than TB, including negative history for MTB in-
fection and without radiological ﬁndings suggestive of MTB
infection in the past and with no signs of active disease,
were chosen as control group. All HIV-positive patients were
excluded from the database.
2.1. IGRA. We used the latest generation IGRA (Quanti-
FERON-TB Gold in-Tube, Cellestis, Carnegie, Australia),
laterreferredtoasQFT-GIT,onallsamples. Peripheralblood
samples were obtained by trained personnel in speciﬁc blood
collection tubes following the manufacturer’s instructions.
All blood samples were processed within 4h of phlebotomy.
Otherwise, the test was performed as previously described
[8].
2.2.TB Culture. Specimenswere stained, processed, and cul-
tured by standard procedures in mycobacteriology [9]. The
isolateswereculturedfor4weeksonL¨ owenstein-Jensen(L-J)
medium at 37◦C and tested for growth rate, pigment pro-
duction, and by biochemical testing using standard methods
[10, 11].
2.3. Statistical Analysis. Data were analyzed using STATA
12.0 (StataCorp, College Station, Texas, USA). The t-test for
independent samples (two-tailed) was carried out to assess
signiﬁcance level of detected diﬀerences in both groups
(IGRA test results, age).
3.Results
A total of 61 patients with active TB as ascertained
through positive MTB culture were examined using QFT-
GIT between 1/2008 and 1/2010 (see Table 1(a)). 53 patients
presented with pulmonary TB, three patients with lymph
node TB, and ﬁve patients with tuberculous pleurisy. The
median QFT-GIT value for all TB patients was 3.46IU/mL,
rangingfrom0.00to300IU/mL.In11patients,thetestresult
was <0.35IU/mL (see Figure 1). Assuming the cutoﬀ for
latent TB suggested by the producer, these are false-negative
(FN) test results (11/61 = 0.18; 18% FN). We calculated the
sensitivity (the proportion of patients with active TB who
are correctly identiﬁed as such) as 1-FN (=82%). Only in
one patient four months after therapy with adalimumab, the
result was 0.00IU/mL, and in one other patient with lung
cancer underconcomitant chemotherapy, it was 0.02IU/mL.
All other patients showed values of 0.07IU/mL or above.
The median age of our patients was 46 years (range: 5–84
years),inthegroupwithatestresult ≥0.07and<0.35IU/mL,
the median age was 80 years (range: 44–84 years), and, in
the group testing ≥0.35IU/mL, it was 36 years (range: 5–84
years).
Within the control group (see Table 1(b)), QFT-GIT val-
ues ranged from 0.00 to 103.4IU/mL in one patient with
pneumonia. The median was 0.00IU/mL. In 50% of all cases
(116/234), no Interferon gamma (IFN-γ) release was mea-
sured (0.00IU/mL). In 51/234 patients (21%), test resultsTuberculosis Research and Treatment 3
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Figure 1: Range of QFT-GIT values below the cutoﬀ of 0.35IU/mL
for patients with active tuberculosis.
were above 0.35IU/mL.The median agein the control group
w a s6 6y e a r sw i t har a n g ef r o m1t o9 9y e a r s .
Patients in the study group were signiﬁcantly younger
than in the control group and had signiﬁcantly higher QFT-
GIT test results (P<0.05 for both, see Table 1(c)).
4.Discussion
IGRAs are in vitro immunologic diagnostic tests to identify
MTB infection. Latent and active infections are not dif-
ferentiated. Several test systems are commercially available:
QuantiFERON-TBGold(QFT),QuantiFERON-TBGoldin-
Tube (QFT-GIT), both Cellestis Limited, Chadstone, Aus-
tralia, and T-SPOT.TB (OxfordImmunotec, Abingdon,UK).
The QFT-GIT measures IFN-γ responses totheMTB speciﬁc
antigens early secretory antigenic target 6 (ESAT-6), culture
ﬁltrate protein 10 (CFP-10), and Rv2654 (TB 7.7). Their use
in clinical practice is more and more widespread. Whereas
the test was initially conceived to support diagnosis of latent
infection, an increasing body of evidence is published on
its use in detection of active TB infection [12–14]. More
and more guidelines now include recommendations for or
against theuse ofIGRAs inthe diﬀerentialdiagnosis ofactive
TB [15].
Several systematic reviews and meta-analyses have re-
cently been published speciﬁcally on the diagnostic accuracy
of IGRAs in active TB [6, 16, 17]. Strong heterogeneity
between study populations is a major limitation of these
meta-analyses, and most studies had small sample sizes.
Overall, few studies were done with the latest generation
QFT-GIT in areas of low endemicity such as Germany (2
studies in [17], 13 studies in [16]). Among those, even fewer
restricted sensitivity analysis to patients with culturally pro-
ven MTB infection and conﬁrmed HIV-negative status [12,
18].
Speciﬁcitydependshighlyonthedeﬁnitionofthecontrol
group. Pai et al. reported a pooled speciﬁcity of 99% among
non-BCG vaccinated and 96% among BCG-vaccinated low-
risk groups [17]. According to a recent meta-analysis that
did not restrict studies on speciﬁcity to low-risk groups
[6], a situation more compatible to our clinical setting, the
speciﬁcity of QFT-GIT was only 0.79 (95% CI 0.75–0.82). In
our study, 51 out of 234 control patients (21%) showed test
results above 0.35IU/mL, indicative of latent TB according
to the producer. However, this ﬁnding is also consistent with
the expected number of false positives assuming a speciﬁcity
of around 0.8 according to Sester et al. [6]. The retrospective
design of our study does not allow any conclusion about the
test speciﬁcity in our study population.
Sensitivity in these studies was also found to be highly
dependent on the study population, notably local TB preva-
lence, and ranged from 0.58 in a high-prevalence country
[19] to 1.00 in a low-prevalence country [20], when QFT-
GIT was assessed. Diel et al. found a pooled sensitivity of
0.84 (95% CI 0.81–0.87) when including only developed
countries [16],consistentwiththeresultspublishedbySester
et al. (0.77, 95% CI 0.75–0.80) [6].
In our consecutive case series of 61 TB culture positive,
HIV-negative patients in a low-prevalence setting in Ger-
many, we found a sensitivity of82.0% (95% CI:0.696, 0.902)
for the QFT-GIT, when the cutoﬀ recommended for the
diagnosis of latent TB was used (<0.35IU/mL). In a low-
prevalence country suchas Germany witha TB prevalence of
5.4/100,000 inhabitants [21], case ﬁnding is an outstanding
priority in the management of this disease. Therefore, highly
sensitive test systems are needed for screening purposes. If
the use of IGRA in the diﬀerential diagnosis of active TB
is recommended, at least under certain conditions, then
the cut-oﬀ point for active TB should be lower compared
to latent TB, as previously discussed by Davidow [22].
Prospective clinical studies in diﬀerent deﬁned regions, with
high- and low-prevalence of active TB, should be performed
to evaluate the use of IGRAs in the diagnostic workup of TB
patients. The cutoﬀ f o rt h ed e t e c t i o no fl a t e n tT Bd o e sn o t
seem applicable for that purpose.
5.Conclusions
We suggest that the cutoﬀ for the use of IGRA in the dif-
ferential diagnosis of active TB in low incidence settings be
reevaluated. Further prospective studies including clinical
criteriaforTBareneededtodetermineanewcutoﬀforactive
TB.
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